Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ravindra GaneshLindsey M PhilpotDennis M BierleRyan J AndersonLori L ArndtRichard F ArndtTracy L CulbertsonMolly J Destro BorgenSara N HansonBrian D KennedyBrian B KottkeJennifer J LarsenPriya RamarJordan K RosedahlMaria Teresa SevilleLeigh L SpeicherSidna M Tulledge-ScheitelCaroline G WilkerRaymund R RazonablePublished in: The Journal of infectious diseases (2021)
This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.